The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1620
ISSUE 1620
March 24, 2021
Stiripentol (Diacomit) for Dravet Syndrome (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
March 24, 2021 (Issue: 1620)
The FDA has approved stiripentol (Diacomit – Biocodex)
for treatment of seizures in patients ≥2 years old with
Dravet syndrome who are also taking clobazam (Onfi).
Stiripentol, which has been available in Europe, Canada,
and Japan for many years, is the second drug to be
approved in the US for this indication; cannabidiol oral
solution (Epidiolex), a purified marijuana product, was
the first.
... more
- Cannabidiol (Epidiolex) for epilepsy. Med Lett Drugs Ther 2018; 60:182.
- MS Cooper et al. Mortality in Dravet syndrome. Epilepsy Res 2016; 128:43.
- ML Buck and HP Goodkin. Stiripentol: a novel antiseizure medication for the management of Dravet syndrome. Ann Pharmacother 2019; 53:1136.
- C Chiron and O Dulac. The pharmacologic treatment of Dravet syndrome. Epilepsia 2011; 52(Suppl 2):72.
- C Chiron et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet 2000; 356:1638.
- FDA Clinical Review. Diacomit, Stiripentol. Available at: http://bit.ly/3tp9dE6. Accessed March 23, 2021.
- C Chiron et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia 2018, 59:1705.
- S Balestrini and SM Sisodiya. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand 2017; 135:73.
- O Devinsky et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017; 376:2011.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2020 September 10 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Stiripentol (Diacomit) for Dravet Syndrome (online only)
Article code: 1620c
Electronic, downloadable article - $45
Article code: 1620c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian